CarrieBrownsteinMD

Vice President, Clinical Development

Dr. Brownstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Columbia University Department Pediatrics
3959 Broadway
New York, NY 10032
Phone+1 212-927-3214

Fax+1 212-544-1974

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1999 - 2002
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 1996 - 1999
Tufts University School of MedicineClass of 1996

PubMed

3 citations
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Sarah A. Holstein, Nizar J. Bahlis, P. Leif Bergsagel, Manisha Bhutani, Niccolo Bolli
Transplantation and Cellular Therapy. 2021-10-01
45 citations
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher, Albiruni Ryan Abdul Razak, Katherine Van Loon
Clinical Cancer Research. 2016-03-15
113 citations
Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Sma...
Suresh S. Ramalingam, David R. Spigel, David Y. Chen, Martin Steins, Jeffrey A. Engelman
Journal of Clinical Oncology. 2011-12-01

Abstracts/Posters

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized...
Carrie Brownstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...
Carrie Brownstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermedi...
Carrie Brownstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
Carrie Brownstein, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
Join now to see all

Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational UpdatesNovember 9th, 2022
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with PfizerOctober 24th, 2022
Cellectis Reports Preliminary Results from Its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual MeetingDecember 5th, 2020
Join now to see all